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The concept of minimal breast cancer (MBC) was introduced in
1971 by Gallager and Martin (Gallager and Martin, 1971) who
attempted to rationalize the terminology of a number of lesions,
including ductal carcinoma in situ (DCIS), lobular carcinoma in
situ (LCIS) and small invasive carcinomas (of less than 0.5cm).
They wished to differentiate these ‘good prognosis’ lesions from
the wider group of carcinomas which comprise ‘early’ breast
cancer and have a variable prognosis. Since then the term
‘minimal breast cancer’ has been extended to include invasive
tumours up to 1cm and in some instances even larger tumours of
good prognostic type, including mucinous, tubular and cribriform
carcinomas (Ackerman and Katzenstein, 1977). Using the TNM
classification most of these cancers would now be included under
the terms Tis, T1a and T1b (Sobin and Wittekind, 1997).
The introduction of breast screening programmes has led to
increased detection of MBCs. DCIS, for instance, has risen from
2–5% of newly diagnosed tumours to 25–30% of those identified
in a screening population (Schnitt et al, 1988; Lagios et al, 1989;
van Dongen et al, 1992). The number of small invasive tumours
detected has also increased, many of these being well-differenti-
ated. The clinical behaviour and prognosis of these in situ and
small invasive tumours is unclear and thus the best method of
treatment has not been established (Schnitt et al, 1988; Harris and
Schnitt, 1990; Rosner & Lane, 1990). New classifications for
DCIS have been proposed in an attempt to determine which cases
are likely to recur or progress to invasion (Millis, 1996; Scott et al,
1997). There are also limited data on the behaviour of small
invasive tumours, particularly those that are well-differentiated.
Numerous trials of treatment are currently underway to define
the best approach to MBC. Questions being addressed are: (a) can
some lesions be treated safely by excision alone?; (b) which
lesions require additional radiotherapy?; and (c) do all invasive
tumours require axillary dissection?
Although we have carried out several studies of pure DCIS we
have not previously evaluated invasive carcinomas within the
category of minimal carcinoma. In an effort to shed light on some
of the above questions we have reviewed lesions so categorized in
our Unit over a 15-year period. In addition to reviewing the
histology we have examined the expression of a number of bio-
logical markers (Ki-67, c-erbB2, p53, oestrogen receptor (ER),
progesterone receptor (PR) and Bcl-2) known to relate to tumour
differentiation and aggression, in order to ascertain the inter-
relationships of these features, and to see whether they relate to
disease outcome in the minimal invasive group of carcinomas.
MATERIALS AND METHODS
Patients
Slides from all cases in the pathology records categorized as
micro- or minimal invasive carcinoma for the period 1975–1990
were reviewed. Although they had all originally been diagnosed as
invasive on review this was not always confirmed. When an inva-
sive component was identified the maximum diameter was
measured and the proportion of DCIS assessed. Cases were cate-
gorized according to the presence or absence of invasion and the
proportion of in situ carcinoma. Patients were excluded if the
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invasive tumour exceeded 1 cm in the original biopsy or subse-
quent wide excision or mastectomy specimens. Also excluded
were stage III or IV carcinomas where the biopsy was incisional
and the entire tumour was never examined histologically. A total
of 98 patients were finally included in the study.
Most patients were diagnosed prior to the National Health
Service (NHS) mammographic screening programme and were
symptomatic (a lump in the majority, but nipple discharge or
Paget’s disease of the nipple in some). Two, however, were diag-
nosed by NHS screening, four by private screening programmes
and in ten other patients mammography contributed to their diag-
nosis in the presence of other symptoms. All except ten patients
were treated by modified radical mastectomy or conservation
therapy (excision plus radiotherapy) without adjuvant therapy. Six
had a simple mastectomy and the remaining four wide excision
with adjuvant tamoxifen in two and radiotherapy in one. None of
the patients treated by less than mastectomy died of this disease.
Follow-up data were available on all but four patients.
Tumour histopathology
The histology was reviewed by two of the authors (RRM and
LGB), and discrepancies were resolved over a double-headed
microscope. Where the presence of invasion was equivocal,
immunohistochemistry with antibodies to basement membrane
(collagen IV and laminin) and to myoepithelial cells (smooth
muscle actin) was undertaken in order to help resolve the problem.
The DCIS and invasive components of each tumour, where
appropriate, were graded. Classification of DCIS as either poorly
differentiated (PD), intermediately differentiated (ID), or well-
differentiated (WD) was carried out according to the classification
recently proposed by a group of European pathologists (Holland et
al, 1994). This classification concentrates primarily on the degree
of nuclear differentiation and secondarily on cellular polarization
around intercellular spaces or towards a duct lumen. The invasive
component was graded according to the modified Bloom and
Richardson criteria (Elston and Ellis, 1991).
Immunohistochemistry
Antibodies used in this study to evaluate biological markers were
MIB-1 (anti-Ki-67, a gift from J Gerdes), 21N (anti-c-erbB2, a gift
from W Gullick, ICRF), DO-7 (anti-p53, Dako, UK), ER-ID5
(anti-ER, Dako, UK), KD68 (anti-PR, Abbott Laboratories, UK),
and Bcl-2-124 (anti-Bcl-2, Dako, UK). At least one representative
paraffin-embedded block from each tumour was selected. Most of
these were obtained from formalin-fixed material, but in a few
cases the only suitable material was methacarn-fixed. Three-
micron sections were cut onto Vectabond™-coated slides, and
dried overnight at 37°C. Microwave-based antigen retrieval,
required for MIB-1, DO-7, ER-ID5 and Bcl-2-124, was carried out
in a microwave oven (800 W, Matsui model 180TC) for 30 min in
0.01 M citrate buffer pH 6. Immunohistochemistry for all anti-
bodies utilized a peroxidase-conjugated streptavidin–biotin
system with DAB (Sigma, UK) as the chromogen. Nuclei were
counterstained with Gill’s haematoxylin.
Controls
Positive controls used were normal tonsil for MIB-1 and Bcl-2,
and breast carcinoma sections known to be positive for each of the
other markers. Negative controls consisted of omission of the
primary antibody on duplicate test sections. Positive staining for
ER, PR and Bcl-2, in benign epithelial cells and in lymphocytes
for Bcl-2, served as internal positive controls for negative staining
tumours.
Assessment of immunostaining
All slides were looked at independently by at least two of the
authors and any difference resolved by consultation. In those
sections containing both in situ and invasive tumour elements,
immunostaining was separately assessed in both areas.
MIB-1 scoring was carried out by counting at least 200 viable
tumour cells in high-power fields, and the percentage of strong
positively stained nuclei calculated. For p53, strong nuclear
staining when present in the majority of tumour cells was consid-
ered positive. All cases with c-erbB2 tumour membrane staining
were scored positive. For ER and PR, cases with immunostaining
in 10% or more tumour nuclei were classed as positive. For Bcl-2,
any cytoplasmic staining in tumour cells was scored as positive.
Two problems were encountered with immunostaining and
assessment. First, MIB1 staining on methacarn-fixed tissue proved
unsatisfactory, and so where suitable formalin-fixed material was
unavailable, such cases were not assessed with this antibody.
Secondly, some very small invasive tumour components were
either cut through or lost during microwaving, and so could not be
assessed.
Statistical analysis
The significance of relationships shown in contingency tables
were evaluated by either a c2 statistic, or by Fisher’s exact test,
where numbers were small. MIB1 scores were regarded as a
continuous variable and differences between groups were deter-
mined using the Kruskal–Wallis test. Disease-free interval and
overall survival curves for the biological markers and clinico-
pathological data were calculated according to the method of
Kaplan and Meier (1958), and the degree of significance deter-
mined by the log-rank test.
RESULTS
Tumour groups
Although all the cases had originally been considered to be inva-
sive histological review, including immunohistochemistry in some
cases, revealed that definite evidence of invasion was not present
in all of them. Immunohistochemistry for basement membrane
components and myoepithelial cells was carried out in 31 cases
and the presence of invasion was confirmed in 14 and excluded in
17. Although both basement membrane and myoepithelial cells
were stretched and attenuated around glandular elements involved
by DCIS, a complete rim was always present. The presence of
malignant cells outside these components was considered essential
for the diagnosis of invasion.
Histological review revealed three groups of tumour:
(a) 28 predominantly invasive carcinomas less than or equal to
10 mm, with or without associated DCIS (‘predominant
invasive’ group, Figure 1). In these cases the in situ compo-
nent comprised from 0 to 40% of the tumour area, with a
median of 5%. In 14 cases, 5% or less of the tumour1610 EA Dublin et al
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consisted of DCIS, and in six cases no in situ component
was identified
(b) 48 predominantly DCIS lesions with definite, often
multiple, foci of invasion but each less than or equal to
10 mm (‘predominant DCIS’ group, Figure 2). In these
cases the in situ component comprised from 60 to 100%,
with a median of 90%. In 40 cases it comprised 90% or
more, in ten of which the invasive component was too small
to grade. Also included in this group were three other cases
where no stromal invasion could be identified, but in one
there was vascular invasion and in two lymph node metas-
tases, both findings indicating the presence of occult
invasion
(c) 22 pure DCIS lesions without evidence of invasion (‘pure
DCIS’ group).
Clinical and pathological features
The clinical and pathological features of the patients in the three
groups are shown in Table 1. The median diameter of the invasive
component in the predominant invasive group was significantly
larger than that in the predominant DCIS group (P < 0.0001). In
the majority of cases (24/28) in the former group it measured more
than 5 mm. In the predominant DCIS group most (44/48) had inva-
sive foci measuring 5 mm or less. More than one invasive focus
was present in only five cases of the predominant invasive group
compared with multiple invasive foci in half of the predominant
DCIS group.
Tumour type and grade
Most of the invasive carcinomas were of the ductal no special type
(NST) category, but there were also three tubular, one lobular and
one mucinous carcinoma in the predominant invasive group and
three tubular, two lobular and two mucinous mixed carcinomas in
the predominant DCIS group.
The distribution of the different DCIS types and the grade of the
invasive components in the three groups is shown in Table 2. As
can be seen, the two invasive groups show distinct differences.
There is significantly more PD DCIS in the predominant DCIS
group and more WD DCIS in the predominant invasive group
(c2 = 9.7, P = 0.008). There is also a significant difference in the
grade of the invasive components, there being more grade III
tumours in the predominant DCIS group and more of grade I
tumours in the predominant invasive group (c2 = 6.77, P = 0.03).
The distribution of the DCIS type in the pure DCIS group lies
between that seen in the two other groups. There was no signifi-
cant difference in the distribution of DCIS type between the
predominant DCIS and pure DCIS groups (c2 = 3.62, P = 0.16).
There is a significant correlation between tumour grade and
type of associated DCIS (c2 = 43.0, P < 0.0001). Grade I invasive
carcinoma was seen either with WD DCIS (15 cases, 65%) or ID
A
B
Figure 1 Tumours from the predominantly invasive group. (A) Tubular
carcinoma. A small amount of WD in situ carcinoma is present at one corner
of this section. (B) Infiltrating grade II ductal carcinoma with a focus of WD
DCIS
Figure 2 Tumours from the predominantly DCIS group. (A) PD DCIS with
comedo type necrosis and a small area of infiltrating grade III ductal
carcinoma. (B) ID DCIS with a small focus of mucoid carcinoma
A
BDCIS (8 cases, 35%) but never with PD DCIS. Conversely, in
those 16 cases of grade III invasive carcinoma with associated
DCIS, this was always of the PD type. In the case of grade II carci-
noma, there were three cases (13%) with WD DCIS, seven (32%)
with ID DCIS and 12 (55%) with PD DCIS.
Biological marker expression within the three tumour
groups
Since the invasive component was often cut out in the predominant
DCIS group, for the purposes of statistical analysis the DCIS
component score of the predominant DCIS tumours was used. For
the predominant invasive tumours, the invasive component was
used. This allowed the majority of the tumours from these two
groups to be included, and seemed reasonable as it was noted that
where both DCIS and invasive tumour components were present,
they typically expressed markers in a similar manner. Where there
was a difference, this was in in intensity of staining and so did not
affect the final score.
As seen in Table 3, the median MIB-1 value for the predominant
invasive carcinomas was 6.6% (range 0.5–19.7), and the majority
of tumours in this group were positive for ER (70%), PR (74%)
and Bcl-2 (89%). Only a small proportion of cases was positive for
c-erbB2 (7%) and p53 (19%).
Minimal breast cancer: histology and marker expression1611
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Table 1Clinical and pathological features
Predominantly Predominantly Pure DCIS
invasive DCIS
Age (years)
Median 54.5 49 54.5
Range 29–73 30–76 36–86
Nodal status (%)
Positive 6 (23) 9 (20) –
Negative 20 (77) 35 (80) 17 (100)
Unknown 2 4 5
Follow-up (years)
Maximum 17 21 21
Median 10 12 13
Histological diameter
of infiltrative
component (mm)
Median 8.5 1.8 –
Range 2–10 0.1–10 –
Proportion of in situ
component (%)
Median 5 90 –
Range 0–40 60–100a –
aIn three cases there was no obvious stromal invasion but vascular invasion
or nodal metastases were present.
Table 2Distribution of DCIS types and grades of invasion within the three groups of minimally invasive carcinoma
Tumour group
Predominantly invasive Predominantly DCIS Pure DCIS
carcinoma + invasion
DCIS typea/grade n = 28 n = 48 n = 22
WD DCIS 10 (36%) 11 (23%) 5 (23%)
ID DCIS 10 (36%) 8 (17%) 8 (36%)
PD DCIS 6 (21%) 29 (60%) 9 (41%)
DCIS not present 2 (7%) – –
Grade I 13 (46%) 11 (23%) –
Grade II 12 (43%) 10 (21%) –
Grade III 3 (11%) 14 (30%) –
Invasion not present – – 22 (100%)
Invasion too small to grade – 13 (26%)b –
aWD (well-differentiated), ID (intermediately differentiated), PD (poorly differentiated). bThese include three cases with no
obvious stromal invasion, but vascular invasion or nodal metastases were present
Table 3Distribution of biological markers within the three different groups of minimal carcinoma
Group
Predominant invasivea Predominant DCIS with Pure DCIS
invasionb
Marker n (%) n (%) n (%)
Median MIB-1c 6.6 (0.5–19.7) 6.7 (1–25.2) 5.65 (2–15.5)
c-erbB2+ 2 (7) 22 (46) 5 (23)
p53+ 5 (19) 15 (31) 3 (14)
ER+ 19 (70) 30 (63) 19 (86)
PR+ 20 (74) 23 (48) 16 (73)
Bcl-2+ 24 (89) 37 (77) 19 (95)
aResults refer to marker expression in the invasive tumour component. bResults refer to marker expression in the DCIS
tumour component. cFigures in brackets are the range. (Figures are derived from the number of cases which were
evaluable for marker expression.)1612 EA Dublin et al
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The predominant DCIS group showed almost the reverse pattern
of staining. Whilst the median MIB-1 value was similar (6.7%,
range 1–25.2), there were fewer ER-, PR-, and Bcl-2-positive
tumours (63%, 48% and 77%) and more c-erbB2- and p53-
positive cases (46% and 31%).
In the pure DCIS tumours the median MIB-1 value was 5.65%
(range 2–15.5), most were ER- (86%), PR- (73%) and Bcl-2-
positive (95%), whilst relatively few were c-erbB2- and p53-
positive tumours (23% and 14%).
Biological marker expression in relation to DCIS type
and invasive tumour grade
The full results with statistical values are outlined in Tables 4
(DCIS type) and 5 (tumour grade). In summary, all markers
showed statistically significant differences in their expression
reflecting the different DCIS types and tumour grades. The MIB1
median score value increased with loss of differentiation in DCIS
and with increasing tumour grade. Both c-erbB2 and p53 posi-
tivity were significantly associated with poorly differentiated
DCIS and high-grade invasive ductal carcinoma. Positive ER and
PR status were both more frequent in better differentiated DCIS
types and low-grade invasive carcinomas. Bcl-2 positivity was
also significantly associated with better differentiated DCIS and
low-grade invasive tumours, and always stained more strongly in
these tumours than in PD DCIS and high-grade invasive tumours.
Survival data
Three patients with predominant DCIS and one with pure DCIS
were lost to follow-up. After a median follow-up time of 10.5
years (maximum 21 years) of the remaining patients there was
no significant difference in outcome between the three groups
(Figure 3A, c2 = 4.7, P = 0.1). The patients with predominant inva-
sive tumours, however, appeared to do marginally better than the
others and none in this group died of breast cancer. Four of the six
patients with predominant DCIS who died had involved axillary
lymph nodes at diagnosis. Of the three patients with pure DCIS
who died ostensibly of breast cancer, one, whose original tumour
was an intracystic papillary carcinoma, was seen 2 months prior to
death when she had no evidence of recurrent breast disease
although her death certificate stated metastatic breast cancer as the
cause of death. The other two had recurrent breast cancer diag-
nosed on the basis of cytology with no histological confirmation
either in the form of a biopsy or a postmortem examination.
Overall survival was significantly related to the presence of lymph
node metastases (Figure 3B, c2 = 12.5, P < 0.001). There was
also a significant difference in survival according to tumour grade,
with grade III tumours faring worse than the others (Figure 3C,
c2 = 10.79, P = 0.0045). Although overall survival by DCIS type in
the two groups with an invasive component showed no significant
differences between the types (c2 = 2.99, P = 0.22), it was notable
that none of the patients with WD DCIS recurred or died of their
disease.
DISCUSSION
Two main findings emerged from this study. First, it was of interest
to note that an appreciable number of the lesions originally diag-
nosed as invasive were, on review, not considered to show definite
evidence of invasion. Secondly and more significantly, we found
that the two groups of tumours with a definite invasive component
appeared to have differing biology.
Table 4 Biological marker profile within the different DCIS types
DCIS type
WD ID PD c2 P
Marker n (%) n (%) n (%)
Median MIB1a 3.8 (1–10.2) 4.3 (1–15) 10.25 (2.2–25.2) 27.48 0.0001
c-erbB2+ 0 4 (15) 26 (59) 30.74 <0.0001
p53+ 2 (8) 2 (8) 17 (39) 13.35 0.0013
ER+ 23 (89) 24 (92) 20 (46) 22.91 <0.0001
PR+ 21 (84) 23 (89) 12 (27) 34.08 <0.0001
Bcl-2+ 24 (100) 24 (100) 28 (70) 16.67 0.00024
aFigures in brackets are the range. (Figures are derived from the number of cases evaluable for marker expression.)
Table 5 Biological marker profile within the different grades of invasive carcinoma
Grade
I II III c2 P
Marker n (%) n (%) n (%)
Median MIB1a 5.0 (0.0–18.6) 6.8 (2–19.7) 12.6 (6.9–30.2) 11.22 0.004
c-erbB2+ 0 3 (14) 9 (64) 21.64 <0.0001
p53+ 3 (17) 3 (15) 10 (67) 13.22 0.0013
ER+ 17 (85) 14 (70) 4 (29) 11.87 0.0026
PR+ 18 (86) 15 (75) 1 (7) 25.58 <0.0001
Bcl-2+ 21 (100) 18 (95) 3 (20) 36.45 <0.0001
aFigure in brackets are the range. (Figures are derived from the number of cases evaluable for marker expression.)Minimal breast cancer: histology and marker expression 1613
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Figure 3 Kaplan–Meier overall survival curves stratified according to: (A) the three minimal invasive groups; (B) nodal status; (C) tumour gradeAt the time that the majority of these cases were diagnosed, the
presence of any suspicious area was usually interpreted as inva-
sion. However, it is now recognized that several phenomena may
be misinterpreted as invasion, notably extensive cancerization of
lobules, particularly when these lobules also show sclerosing
adenosis. Fibrosis and inflammatory cell reaction around involved
elements can also confound the picture as can tangential cutting.
All of these features are most frequently associated with high-
grade, poorly differentiated DCIS. More recently it has become
apparent, both because of more clearly defined histological criteria
and because of the use of immunohistochemistry with antibodies
to basement membrane and myoepithelial cell antigens, that
invasion has frequently been overdiagnosed and should only be
reported when it is unequivocally present. Careful evaluation,
including the use of immunohistochemistry when appropriate, is
essential. The difficulties of assessing invasion are emphasized in
the present study by the three cases, one with vascular invasion
and the two with lymph node metastases, where no stromal inva-
sion could be identified. In the majority of cases in the study in
which on review the presence of invasion could not be confirmed
the in situ process involved tissue on several slides and showed
widespread cancerization of lobules. In our view, when DCIS is
extensive and involves multiple closely packed glandular
elements, and particularly when it is poorly differentiated, it may
be almost impossible to assess with certainty the presence or
absence of invasion. This point should be stressed in the histology
report. Particularly thought provoking in this respect are reports of
metastatic carcinoma mimicking in situ carcinoma and even
producing fragmented surrounding rims of basement membrane
material (Barsky et al, 1997).
The principal finding of the present study is that the two groups
of tumours with an invasive component included under the catego-
rization of minimal breast cancer in our files appear to be different.
Perhaps surprisingly, those with a predominant in situ component
and a generally smaller invasive component have a more aggres-
sive morphology and pattern of biological marker expression than
the predominant invasive tumours. In many of the former group,
the invasive component was too small to grade, but the in situ
component was usually PD. In view of the now well-established
correlation between tumour grade and DCIS type, it is probable
that the majority of these very small invasive tumours were of
high grade (Lampejo et al, 1994; Moriya and Silverberg, 1994;
Goldstein and Murphy, 1996). This would further enhance the
differences in tumour grade observed between these two groups.
The high incidence of PD DCIS in the predominant DCIS group is
in keeping with reports that high grade or poorly differentiated
DCIS is more often extensive and more often associated with inva-
sion than other types of DCIS (Lagios et al, 1989; Patchefsky et al,
1989; Bellamy et al, 1993). On the other hand, the relatively high
proportion of small grade I invasive carcinomas in the predomi-
nant invasive group is consistent with other studies which have
noted a correlation between tumour grade and tumour size
(Tubiana and Koscielny, 1991; Tabàr et al, 1992).
In terms of prognosis it is not possible to show any significant
differences in outcome between the three groups. The tumour
types included in this study are known to be associated with a
favourable prognosis. It is of interest, however, that although not
statistically significant, the predominant and pure DCIS groups
fared slightly worse. Perhaps relevant to this is a study of small
invasive carcinomas (≤ 1 cm) in which those with a predominant
DCIS component (at least 2–4 times greater than the invasive
component) were significantly more frequently associated with
positive lymph nodes and had a higher local recurrence rate than
those with a smaller DCIS component (Sinn et al, 1994). Although
in our study we did not find any difference in the incidence of posi-
tive axillary nodes between the two invasive groups, the overall
incidence (21%) is similar to that reported by others in association
with invasive carcinomas < 10 mm. The prognostic significance of
1614 EA Dublin et al
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axillary nodal status is also in agreement with others who, like us,
have found that this together with tumour grade is the most signifi-
cant prognostic marker in small invasive carcinomas (Joensuu
and Toikkanen, 1991; Arnesson et al, 1994; Mustafa et al, 1998;
Querzoli et al, 1998).
Some biological markers, including those used in this present
study, have been shown to be preferentially expressed by certain
classes of tumour, and in the case of DCIS have shown correlation
with different histological types (Millis et al, 1996; Mack et al,
1997). This may prove to have prognostic implications, as has
been shown with invasive carcinoma. Our findings regarding
marker expression and DCIS type and tumour grade are broadly
similar to those previously reported. High expression of MIB-1, c-
erbB2 and p53 were all associated with PD DCIS and high-grade
invasive tumours, whilst ER, PR and Bcl-2 were more commonly
expressed in better differentiated DCIS and low-grade invasive
tumours (Lovekin et al, 1991; Barnes et al, 1993; Nathan et al,
1994; Millis et al, 1996; Veronese and Maisano, 1996). We also
found that marker expression was similar in DCIS and invasive
components where both were present. Thus, the differences in
marker expression noted between the groups reflected the morpho-
logical differences. That is to say, a high proliferative index and an
increased incidence of c-erbB2 and p53 expression, was typical of
the predominant DCIS group which contained many PD DCIS,
high-grade tumours. In contrast, an increased incidence of ER, PR
and Bcl-2 expression more frequently occurred in the predominant
invasive group which were chiefly low grade.
A recent paper on biological markers in minimal breast carci-
nomas divided the cases into pure DCIS, mixed invasive/in situ
carcinomas with more than 50% of the tumour area comprised of
in situ carcinoma and invasive carcinomas (Querzoli et al, 1998).
Although these are not identical to our subgroups there was a
similar relationship with the biological markers. Steroid receptors
were lowest in the mixed group and highest in the invasive group,
whilst proliferative activity, p53 and c-erbB2 proteins were all
higher in the mixed than in the invasive group. The authors
suggest that biological phenotype can be integrated with tradi-
tional pathological indicators for accurate staging of patients.
In the present study there was a relatively low incidence of
expression of both c-erbB2 and p53 in the pure in situ carcinomas
when compared with most reports of DCIS, including our own
previous studies (Bartkova et al, 1990; Bobrow et al, 1994). This
inconsistent result is likely to be an aberration produced by the
small number of pure DCIS tumours included in the current study.
The incidence of expression of these two markers in the two inva-
sive groups combined together, however, is consistent with the
literature on invasive tumours (Lovekin et al, 1991).
The well-documented discrepancy in the incidence of expres-
sion of the c-erbB2 oncoprotein between pure in situ carcinoma
and invasive carcinoma is not understood (Allred et al, 1992).
Although there is an association between high-grade invasive
carcinoma and expression of the oncoprotein, the incidence of
expression in grade III tumours is not as high as that seen in poorly
differentiated, high-grade DCIS. We previously suggested that this
might be due to some grade III carcinomas having only a transi-
tory in situ phase with rapid progression to invasion, so not
allowing time for detection as pure in situ carcinoma (Barnes et al,
1992). Whilst one could postulate that extensive DCIS with small
foci of invasion would have an intermediate level of c-erbB2
expression, this view was not substantiated in the present study
where the predominant DCIS group of tumours show the same
proportion of positive cases as reported in most invasive carci-
nomas.
There is a continuing debate as how to best manage patients
with small invasive breast carcinoma (of 1 cm or less). It is still
unclear whether more conservative approaches such as excision
biopsy alone with close follow-up are appropriate, or whether
more aggressive treatment is required. It is our view that catego-
rizing these lesions according to their morphology and biology,
rather than treating them as one homogeneous group of tumours
will determine more accurately suitable treatment. It would appear
from this study that the small predominant invasive carcinomas
and the predominant DCIS lesions are manifestations of two
distinct tumour biologies. The latter is a phenomenon most associ-
ated with tumours having aggressive characteristics and thus they
may merit a more rigorous approach in patient management.
Many more women with small invasive carcinomas will appear
in clinics as a result of breast screening programmes and more
information about their biology will accrue giving studies such as
the present one greater statistical power. This will enable more
informed discussion as to the best management for these different
subgroups of what have previously been termed minimal breast
cancer.
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